ArticleTissue engineering. Part C, Methods2012
Compartmental hollow fiber capillary membrane-based bioreactor technology for in vitro studies on red blood cell lineage direction of hematopoietic stem cells.
Article in Tissue engineering. Part C, Methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 54 citations in OpenAlex.
- Bioartificial liver: Where lies the path ahead-A review.Hepatology communications · 2025Review
- Bioprinting Soft 3D Models of Hematopoiesis using Natural Silk Fibroin-Based Bioink Efficiently Supports Platelet Differentiation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Current status of red blood cell manufacturing in 3D culture and bioreactors.Blood research · 2023Review
- Expansion and differentiation of ex vivo cultured erythroblasts in scalable stirred bioreactors.Biotechnology and bioengineering · 2022Article
- Therapeutic use of red blood cells and platelets derived from human cord blood stem cells.Stem cells translational medicine · 2021Review
- Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and plateletsHaematologica · 2021Review
- Scale-Up Technologies for the Manufacture of Adherent Cells.Frontiers in nutrition · 2020Review
- Ceramic Hollow Fibre Constructs for Continuous Perfusion and Cell Harvest from 3D Hematopoietic Organoids.Stem cells international · 2018Article
- Modelling mesenchymal stromal cell growth in a packed bed bioreactor with a gas permeable wall.PloS one · 2018Article
- Polyurethane scaffolds seeded with CD34(+) cells maintain early stem cells whilst also facilitating prolonged egress of haematopoietic progenitors.Scientific reports · 2016Article
- Small-Scale Perfusion Bioreactor of Red Blood Cells for Dynamic Studies of Cellular Pathways: Proof-of-Concept.Frontiers in molecular biosciences · 2016Article
- Red blood cell generation by three-dimensional aggregate cultivation of late erythroblasts.Tissue engineering. Part A · 2015Article
- Transdifferentiation of Human Hair Follicle Mesenchymal Stem Cells into Red Blood Cells by OCT4.Stem cells international · 2015Article
- Manufacturing blood ex vivo: a futuristic approach to deal with the supply and safety concerns.Frontiers in cell and developmental biology · 2014Review
- Stem cell-derived erythrocytes as upcoming players in blood transfusion.ISBT science series · 2013Article
- Concise review: production of cultured red blood cells from stem cells.Stem cells translational medicine · 2012Review
- The potential of stem cells as an in vitro source of red blood cells for transfusion.Cell stem cell · 2012Review
- Serum-free spheroid suspension culture maintains mesenchymal stem cell proliferation and differentiation potential.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
Continuous production of red blood cells (RBCs) in an automated closed culture system using hematopoietic stem cell (HSC) progenitor cell populations is of interest for clinical application because of the high demand for blood transfusions. Previously, we introduced a four-compartment bioreactor that consisted of two bundles of hollow fiber microfiltration membranes for transport of culture medium (forming two medium compartments), interwoven with one bundle of hollow fiber membranes for transport of oxygen (O(2)), carbon dioxide (CO(2)), and other gases (forming one gas compartment). Small-scale prototypes were developed of the three-dimensional (3D) perfusion cell culture systems, which enable convection-based mass transfer and integral oxygenation in the cell compartment. CD34(+) HSC were isolated from human cord blood units using a magnetic separation procedure. Cells were inoculated into 2- or 8-mL scaled-down versions of the previously designed 800-mL cell compartment devices and perfused with erythrocyte proliferation and differentiation medium. First, using the small-scale 2-mL analytical scale bioreactor, with an initial seeding density of 800,000 cells/mL, we demonstrated approximately 100-fold cell expansion and differentiation after 7 days of culture. An 8-mL laboratory-scale bioreactor was then used to show pseudocontinuous production by intermediately harvesting cells. Subsequently, we were able to use a model to demonstrate semicontinuous production with up to 14,288-fold expansion using seeding densities of 800,000 cells/mL. The down-scaled culture technology allows for expansion of CD34(+) cells and stimulating these progenitors towards RBC lineage, expressing approximately 40% CD235(+) and enucleation. The 3D perfusion technology provides an innovative tool for studies on RBC production, which is scalable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.